{"groups":[{"description":"IPH2101 Fully human anti-KIR monoclonal antibody : 0.2mg/Kg , every 4 weeks by intravenous route over 1 hour, for 4 cycles. Patients responding at 4 months will be allowed to receive an additional period of treatment of 4 monthly.","id":"FG000","title":"Arm A: IPH2101 0.2mg/Kg"},{"description":"IPH2101 Fully human anti-KIR monoclonal antibody : 2mg/Kg , every 4 weeks by intravenous route over 1 hour, for 4 cycles. Patients responding at 4 months will be allowed to receive an additional period of treatment of 4 monthly.","id":"FG001","title":"Arm B: IPH2101 2mg/kg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All patients enrolled in the study were analyzed. There was no screen failure during the trial conduct.","recruitmentDetails":"Patients were recruited in France at the public hospital (10 actives center), from mid of November 2009 to end of October 2011."}